Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

P. D. Le Coutre*, F. J. Giles, A. Hochhaus, J. F. Apperley, G. J. Ossenkoppele, R. Blakesley, Y. Shou, N. J. Gallagher, M. Baccarani, J. Cortes, H. M. Kantarjian

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib in patients with Ph + chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results'. Together they form a unique fingerprint.

Medicine & Life Sciences